{"id":2130,"date":"2025-09-20T13:55:13","date_gmt":"2025-09-20T11:55:13","guid":{"rendered":"https:\/\/galpharma.tn\/?post_type=medicament&#038;p=2130"},"modified":"2025-09-20T13:55:13","modified_gmt":"2025-09-20T11:55:13","slug":"gliptamet","status":"publish","type":"medicament","link":"https:\/\/galpharma.tn\/en\/medicaments\/gliptamet\/","title":{"rendered":"GLIPTAMET"},"content":{"rendered":"<p><span class=\"Y2IQFc\" lang=\"en\">Patients with type 2 diabetes mellitus (T2DM):<\/span><\/p>\n<ul>\n<li class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" tabindex=\"-1\" role=\"text\" data-placeholder=\"Traduction\" data-ved=\"2ahUKEwjA-q3cgeePAxUTzQIHHUqCG6oQ3ewLegQIChAV\" aria-label=\"Texte traduit\u00a0: Patients with type 2 diabetes mellitus (T2DM): GLIPTAMET is indicated as adjunctive therapy with diet and exercise in patients in whom metformin hydrochloride or vildagliptin monotherapy has not achieved adequate glycaemic control, or in patients already receiving treatment with a free combination of metformin hydrochloride and vildagliptin. GLIPTAMET is indicated in combination with a sulfonylurea (i.e., triple combination) as adjunctive therapy with diet and exercise in patients in whom treatment with metformin and a sulfonylurea alone does not achieve adequate glycaemic control. GLIPTAMET is indicated in combination with insulin to improve glycaemic control in patients in whom diet, exercise, and treatment with a stable dose of insulin and metformin do not achieve adequate glycaemic control.\"><span class=\"Y2IQFc\" lang=\"en\"> GLIPTAMET is indicated as adjunctive therapy with diet and exercise in patients in whom metformin hydrochloride or vildagliptin monotherapy has not achieved adequate glycaemic control, or in patients already receiving treatment with a free combination of metformin hydrochloride and vildagliptin. <\/span><\/li>\n<li class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" tabindex=\"-1\" role=\"text\" data-placeholder=\"Traduction\" data-ved=\"2ahUKEwjA-q3cgeePAxUTzQIHHUqCG6oQ3ewLegQIChAV\" aria-label=\"Texte traduit\u00a0: Patients with type 2 diabetes mellitus (T2DM): GLIPTAMET is indicated as adjunctive therapy with diet and exercise in patients in whom metformin hydrochloride or vildagliptin monotherapy has not achieved adequate glycaemic control, or in patients already receiving treatment with a free combination of metformin hydrochloride and vildagliptin. GLIPTAMET is indicated in combination with a sulfonylurea (i.e., triple combination) as adjunctive therapy with diet and exercise in patients in whom treatment with metformin and a sulfonylurea alone does not achieve adequate glycaemic control. GLIPTAMET is indicated in combination with insulin to improve glycaemic control in patients in whom diet, exercise, and treatment with a stable dose of insulin and metformin do not achieve adequate glycaemic control.\"><span class=\"Y2IQFc\" lang=\"en\">GLIPTAMET is indicated in combination with a sulfonylurea (i.e., triple combination) as adjunctive therapy with diet and exercise in patients in whom treatment with metformin and a sulfonylurea alone does not achieve adequate glycaemic control.<\/span><\/li>\n<li class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" tabindex=\"-1\" role=\"text\" data-placeholder=\"Traduction\" data-ved=\"2ahUKEwjA-q3cgeePAxUTzQIHHUqCG6oQ3ewLegQIChAV\" aria-label=\"Texte traduit\u00a0: Patients with type 2 diabetes mellitus (T2DM): GLIPTAMET is indicated as adjunctive therapy with diet and exercise in patients in whom metformin hydrochloride or vildagliptin monotherapy has not achieved adequate glycaemic control, or in patients already receiving treatment with a free combination of metformin hydrochloride and vildagliptin. GLIPTAMET is indicated in combination with a sulfonylurea (i.e., triple combination) as adjunctive therapy with diet and exercise in patients in whom treatment with metformin and a sulfonylurea alone does not achieve adequate glycaemic control. GLIPTAMET is indicated in combination with insulin to improve glycaemic control in patients in whom diet, exercise, and treatment with a stable dose of insulin and metformin do not achieve adequate glycaemic control.\"><span class=\"Y2IQFc\" lang=\"en\"> GLIPTAMET is indicated in combination with insulin to improve glycaemic control in patients in whom diet, exercise, and treatment with a stable dose of insulin and metformin do not achieve adequate glycaemic control.<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Patients with type 2 diabetes mellitus (T2DM): GLIPTAMET is indicated as adjunctive therapy with diet and exercise in patients in whom metformin hydrochloride or vildagliptin monotherapy has not achieved adequate glycaemic control, or in patients already receiving treatment with a free combination of metformin hydrochloride and vildagliptin. GLIPTAMET is indicated in combination with a sulfonylurea [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"template":"","class_list":["post-2130","medicament","type-medicament","status-publish","hentry","dci-vildagliptin","class_therapeutique-metabolism-and-nutrition","class_therapeutique-digestive-system-and-metabolism","galenique-coated-tablets"],"_links":{"self":[{"href":"https:\/\/galpharma.tn\/en\/wp-json\/wp\/v2\/medicament\/2130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/galpharma.tn\/en\/wp-json\/wp\/v2\/medicament"}],"about":[{"href":"https:\/\/galpharma.tn\/en\/wp-json\/wp\/v2\/types\/medicament"}],"wp:attachment":[{"href":"https:\/\/galpharma.tn\/en\/wp-json\/wp\/v2\/media?parent=2130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}